Brief: Evofem Biosciences Announces Completion Of Last Subject Last Visit (Lslv) In Registrational Phase 3 "Evoguard" Trial Evaluating Phexxi® For The Prevention Of Chlamydia And Gonorrhea In Women

Evofem Biosciences

01/08/2022 14:32

Aug 1 (Reuters) - Evofem Biosciences Inc  EVFM.O :
    * EVOFEM ANNOUNCES COMPLETION OF LAST SUBJECT LAST VISIT
(LSLV) IN
REGISTRATIONAL PHASE 3 "EVOGUARD" TRIAL EVALUATING PHEXXI® FOR
THE PREVENTION OF CHLAMYDIA AND GONORRHEA IN WOMEN
    * EVOFEM BIOSCIENCES INC - U.S. REGULATORY SUBMISSION
PLANNED FOR
FIRST HALF OF 2023
    * EVOFEM BIOSCIENCES INC- U.S. REGULATORY SUBMISSION PLANNED
FOR
FIRST HALF OF 2023
    * EVOFEM BIOSCIENCES INC - TOP-LINE READOUT OF DATA EXPECTED
IN
OCTOBER 2022
    * EVOFEM BIOSCIENCES INC - PHEXXI IS CURRENTLY APPROVED IN
U.S.
FOR PREVENTION OF PREGNANCY

Source text for Eikon:  ID:nPn4ghGgPa 
Further company coverage:  EVFM.O 

 ((reuters.briefs@thomsonreuters.com;))